Conference
Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.
Abstract
6041
Background: Dacomitinib is an irreversible pan-HER TKI with preclinical (EGFRvIII+ cell lines, SCCHN xenografts) and clinical activity (phase II recurrent/metastatic SCCHN; Razak et al, Ann Oncol 2012). However, little is known about predictive markers of efficacy related to EGFR signalling in this setting. Methods: Of69 pts treated with 1st-line dacomitinib in a phase II trial for recurrent/metastatic SCCHN, 48 pts had …
Authors
Audet M-L; Allo G; Weng X; Kim L; Gologan O; Kamel-Reid S; Siu L; Coutlee F; Laurie SA; Hotte SJ
Volume
31
Pagination
pp. 6041-6041
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.6041
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X